Kineta Receives $1,627,498 New Round

  • Feed Type
  • Date
  • Company Name
  • Mailing Address
    219 Terry Ave N Seattle, WA 98109 USA
  • Company Description
    Through Kineta, our pioneering team is dedicated to further study of innate immunity with an aggressive strategy to develop early stage programs for powerful new antiviral and immune modulating drugs.
  • Website
  • Transaction Type
    Venture Equity
  • Transaction Amount
  • Transaction Round
  • Proceeds Purposes
    Proceeds purposes were not disclosed. SEC regulatory filing. Contact technology company for investment details, if applicable. Not an offer or solicitation for sale of securities.
  • M&A Terms
  • Venture Investor